Simtriyo is a first-in-class ADHD treatment that targets norepinephrine, dopamine, and serotonin. It’s also a CNS stimulant.¹

The mechanism of action of Simtriyo in the treatment of ADHD is unclear; however, its efficacy could be mediated through its activity as an NDSRI.

An NDSRI is a norepinephrine-dopamine-serotonin reuptake inhibitor. Simtriyo is the first and only NDSRI and CNS stimulant that is FDA approved to treat ADHD.¹

The Simtriyo pharmacokinetic profile is designed to support once-daily dosing. Capsules contain a combination of immediate release, sustained release, and delayed release beads. Patients achieve peak concentration at 5 hours post-dose and steady state is reached by the second day.¹